<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        6-5547-21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FAMPYRA 10MG Prolonged-release tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FAMPRIDINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1133.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ALKERMES PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ALKERMES PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Biogen Idec B.V-Natherland
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N07XX07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Fampyra contains the active substance fampridine which belongs to a group of medicines called potassium channel blockers. They work by stopping potassium leaving the nerve cells which have been damaged by MS. This medicine is thought to work by letting signals pass down the nerve more normally, which allows you to walk better.</p><p>Fampyra is a medicine used to improve walking in adults (18 years and over) with Multiple Sclerosis (MS) related walking disability. In multiple sclerosis, inflammation destroys the protective sheath around the nerves leading to muscle weakness, muscle stiffness and difficulty walking.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p><strong>Do not take Fampyra</strong></p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic</strong> to fampridine or any of the other ingredients of this medicine (listed in section 6)</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a seizure or have ever had a <strong>seizure</strong> (also referred to as a fit or convulsion)</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your doctor or nurse has told you that you have moderate or severe <strong>kidney problems</strong></p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking a medicine called cimetidine</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>taking any other medicine containing fampridine</strong>. This may increase your risk of serious side effects</p><p>&nbsp;</p><p><strong>Tell your doctor </strong>and<strong> do not take</strong> Fampyra if any of these apply to you.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Fampyra:</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you feel aware of your heartbeat (<em>palpitations</em>)</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are prone to infections</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any factors or are taking any medicine which affects your risk of fits (<em>seizure</em>)</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have been told by a doctor that you have mild problems with your kidneys</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have history of allergic reactions</p><p>You should use a walking aid, such as a cane, as needed because this medicine may make you feel dizzy or unsteady this may result in an increased risk of falls</p><p><strong>Tell your doctor before you take</strong> Fampyra if any of these apply to you.</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children or adolescents under the age of 18 years.</p><p><strong>Elderly</strong></p><p>Before starting treatment and during treatment your doctor may check that your kidneys are working properly.</p><p><strong>Other medicines and Fampyra</strong></p><p><strong>Tell your doctor or pharmacist</strong> if you are taking, have recently taken or might take any other medicines.</p><p><strong>Do not take Fampyra if you are taking any other medicine containing fampridine.</strong></p><p><strong>Other medicines that affect the kidneys </strong></p><p>Your doctor will be especially careful if fampridine is given at the same time as any medicine which may affect how your kidneys eliminate medicines for example carvedilol, propranolol and metformin.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Fampyra is not recommended during pregnancy.</p><p>Your doctor will consider the benefit of you being treated with Fampyra against the risk to your baby.</p><p><strong>You should not </strong>breast-feed whilst taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Fampyra may have an effect on people&rsquo;s ability to drive or use machines, it can cause dizziness.&nbsp; Make sure you are not affected before you start driving or use machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Fampyra is only available by prescription and under the supervision of doctors experienced in MS.</p><p>Your doctor will give you an initial prescription for 2 to 4 weeks. After 2 to 4 weeks the treatment will be reassessed.</p><p><strong>The recommended dose is</strong></p><p><strong>One</strong> tablet in the morning and <strong>one</strong> tablet in the evening (12 hours apart). Do not take more than two tablets in a day<strong>. You must leave 12 hours</strong> between each tablet. Do not take the tablets more often than every 12 hours.</p><p>Fampyra is for oral use.</p><p><strong>Swallow each tablet whole</strong>, with a drink of water. Do not divide, crush, dissolve, suck or chew the tablet. This may increase your risk of side effects.</p><p>This medicine should be taken without food, on an empty stomach.</p><p>&nbsp;</p><p>The bottle will also contain a desiccant. Leave the desiccant in the bottle, do not swallow it.</p><p><strong>&nbsp;</strong></p><p><strong>If you take more Fampyra than you should</strong></p><p>Contact your doctor immediately if you take too many tablets.</p><p>Take the Fampyra box with you if you go to see the doctor.</p><p>In overdose you may notice sweating, minor shaking (<em>tremor</em>), dizziness, confusion, memory loss (<em>amnesia</em>) and fits (<em>seizure</em>). You may also notice other effects not listed here.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>If you forget to take Fampyra </strong></p><p>If you forget to take a tablet, do not take two tablets at once to make up for a missed dose. You must <strong>always leave 12 hours</strong> between each tablet.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>If you have a seizure, stop taking Fampyra</strong> and tell your doctor immediately.</p><p>If you experience one or more of the following allergic (<em>hypersensitivity</em>) symptoms: swollen face, mouth, lips, throat or tongue, reddening or itching of the skin, chest tightness and breathing problems <strong>stop taking Fampyra</strong> and see your doctor immediately.</p><p>Side effects are listed below by frequency:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>Very common side effects</strong></p><p>May affect more than 1 in 10 people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract infection</p><p><strong>Common side effects</strong></p><p>May affect up to 1 in 10 people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling unsteady</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Spinning sensation <em>(vertigo)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling weak and tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Minor shaking (<em>tremor</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness or tingling of skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common cold (<em>nasopharyngitis</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu (<em>influenza</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Viral infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty breathing (<em>shortness of breath</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (<em>nausea</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being sick (<em>vomiting</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Upset stomach</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heartbeat that you can feel (<em>palpitations</em>)</p><p><strong>Uncommon side effects</strong></p><p>May affect up to 1 in 100 people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fits (<em>seizure</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction (<em>hypersensitivity</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergy (<em>anaphylactic reaction</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, mouth or tongue (<em>angioedema</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New onset or worsening of nerve pain in the face (<em>trigeminal neuralgia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast heart rate (<em>tachycardia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness or loss of consciousness (<em>hypotension</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash/itchy rash (<em>urticaria</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest discomfort</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Section 6 of this leaflet.</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the package after EXP. The expiry date refers to the last day of that month.</p><p>Store below 30&deg;C. Store the tablets in the original package in order to protect from light and moisture.</p><p>Only one bottle should be opened at a time. After first opening use within 7 days.</p><p>Do not throw away any medicines via waste water or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is fampridine.</p><p>Each prolonged-release tablet contains 10 mg of fampridine</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients<strong> </strong>are:</p><p>Tablet core: hypromellose, microcrystalline cellulose, silica colloidal anhydrous, magnesium stearate; film coat: hypromellose, titanium dioxide (E-171), polyethylene glycol 400</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 Fampyra is an off-white, film coated, oval biconvex 13 x 8 mm prolonged-release tablet with A10 on one side.
Fampyra comes in HDPE (high-density polyethylene) bottles. Each bottle contains 14 prolonged-release tablets and a silica gel desiccant. Each pack contains 56 prolonged-release tablets (4 bottles).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Biogen Netherlands B.V.</p><p>Prins Mauritslaan 13</p><p>1171 LP Badhoevedorp</p><p>The Netherlands</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Alkermes Pharma Ireland Ltd, Monksland, Athlone, Co Westmeath, Ireland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                  05/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;</p><p dir="RTL">ويحتوي الدواء فامبيرا على المكون الفعال فامبريدينfampridine &nbsp;الذي ينتمي إلى مجموعة من الأدوية تسمى باسم حاصرات قنوات&nbsp; البوتاسيوم .potassium channel blockersوهي تعمل عن طريق إيقاف مغادرة البوتاسيوم من الخلايا العصبية التي تعرضت للتلف بفعل مرض التصلب اللويحي المتعدد.MS ومن المعتقد أن هذا الدواء يحقق مفعوله من خلال السماح للإشارات العصبية بالمرور عبر العصب بصورة عادية مما يسمح لك بالمشي بطريقة أفضل.</p><p dir="RTL">فامبيرا هو دواء يُستخدم لتحسين المشي عند البالغين (18 عامًا فأكثر) المصابين بالتصلب المتعدد (MS) المرتبط بإعاقة المشي. في حالة التصلب المتعدد، يؤدي الالتهاب إلى تدمير الغلاف الواقي حول الأعصاب، مما يؤدي إلى ضعف في العضل وتصلب العضلات وصعوبة في المشي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لا</strong><strong> </strong><strong>تستعمل</strong><strong> </strong><strong>الدواء</strong><strong> </strong><strong>فامبيرا</strong><strong> Fampyra </strong><strong>&nbsp;في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية:</strong></p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>حساسية</strong><strong> </strong>من مادة فامبريدين fampridine أو أي مادة من المكونات الأخرى في هذا الدواء (المدرجة في القسم (6</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو عانيت من قبل من <strong>نوبات صرع</strong>) ويشار إليها أيضًا باسم اختلاجات أو تشنجات(</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك الطبيب أو الممرض أنك تعاني من <strong>مشاكل </strong>متوسطة أو حادة <strong>في الكلى</strong>.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول دواء يسمى سيمتيدين cimetidine</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تتناول أي دواء آخر يحتوي على فامبريدين</strong>، فقد يؤدي ذلك إلى زيادة احتمال الإصابة بأعراض جانبية خطيرة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحدث إلى طبيبك ولا تتناول</strong> الدواء فامبيرا&nbsp;&nbsp;&nbsp; Fampyra&nbsp;&nbsp; في حال تنطبق عليك أي من هذه الحالات</p><p dir="RTL"><strong>التحذيرات</strong><strong> </strong><strong>والاحتياطات:</strong></p><p dir="RTL"><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong> </strong><strong>الخاص</strong><strong> </strong><strong>بك</strong><strong> </strong><strong>قبل</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>فامبيرا</strong><strong>:Fampyra</strong></p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تشعر بضربات القلب (<em>ضربات القلب السريعة</em>)</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت عرضة للإصابة بالتهابات</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي عوامل أخرى أو إذا كنت تتناول أي دواء يؤثر على احتمال إصابتك بنوبات مرضية &nbsp;)<em>نوبات الصرع</em>).</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك الطبيب أنك تعاني من مشكلات بسيطة في الكلى</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ من ردود الفعل التحسسية</p><p dir="RTL">يجب عليك استخدام أداة مساعدة على المشي، مثل العصا، حسب الحاجة لأن هذا الدواء قد يجعلك تشعر بالدوار أو عدم الاستقرار، وقد يؤدي ذلك إلى زيادة تعرضّك لخطر السقوط.</p><p dir="RTL"><strong>أخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>قبل</strong><strong> </strong>أن تتناول الدواء <strong>فامبيرا </strong><strong>Fampyra</strong> إذا كانت أي من هذه تنطبق عليك.&nbsp;</p><p dir="RTL"><strong>الأطفال</strong><strong> </strong><strong>و</strong><strong>المراهقون: </strong><strong>&nbsp;</strong></p><p dir="RTL">لا تعطِ &nbsp;هذا الدواء &nbsp;للأطفال أو المراهقين تحت سن 18 سنة.</p><p dir="RTL"><strong>لكبار</strong><strong> </strong><strong>السن</strong></p><p dir="RTL">قبل بدء العلاج وأثناء العلاج قد يقوم طبيبك بفحص كليتيك للتأكد من أنهما تعملان بكيفية سليمة.</p><p dir="RTL"><strong>فامبيرا </strong><strong>Fampyra</strong><strong> و الأدوية</strong><strong> </strong><strong>الأخرى </strong></p><p dir="RTL"><strong>أخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong> </strong>إذا <strong>كنت</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>تناولت</strong> مؤخرًا <strong>أو</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تتناول</strong> أي أدوية أخرى.<strong> </strong></p><p dir="RTL"><strong>لا</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>الدواء</strong><strong> </strong><strong>فامبيرا </strong><strong>Fampyra</strong><strong> إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أدوية أخرى</strong><strong> </strong><strong>تحتوي</strong><strong> </strong><strong>على</strong><strong> </strong><strong>فامبريدين</strong></p><p dir="RTL"><strong>الأدوية</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>التي</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الكليتين</strong></p><p dir="RTL">سوف يتوخى طبيبك الحرص بصفة خاصة في حالة إعطائك لدواء فامبريدين في نفس الوقت الذي تتناول فيه أي دواء قد يؤثر على</p><p dir="RTL">كيفية قيام الكلى بوظيفتها في التخلص من الأدوية، فعلى سبيل المثال كارفيديلول carvedilol وبروبرانولول propranolol &nbsp;وميتفورمين .metformin</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنت حاملاً أو تقومين بالرضاعة الطبيعية، أو تعتقدين أنك حاملاً أو أنكِ تخططين لإنجاب طفل، تحدثي مع طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">لا يوصى بتناول الدواء فامبيرا Fampyra أثناء فترة الحمل.</p><p dir="RTL">سوف يأخذ طبيبك في الأعتبار فائدة علاجك بدواء فامبيرا Fampyra ومدى خطورة ذلك على طفلك الرضيع.</p><p dir="RTL"><strong>يجب</strong><strong> </strong><strong>عدم</strong><strong> </strong><strong>الإرضاع </strong>أثناء تناول هذا الدواء.</p><p dir="RTL"><strong>قيادة</strong><strong> </strong><strong>السيارات</strong><strong> </strong><strong>واستعمال</strong><strong> </strong><strong>الماكينات</strong></p><p dir="RTL">قد يكون لدواء فامبيرا Fampyra تأثير على قدرة الشخص على قيادة السيارة أو استعمال الماكينات فالدواء يسبب دوارًا. تأكد من عدم تأثرك بالدواء قبل أن تبدأ قيادة السيارة أو استعمال الماكينات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">تناول دائمًا هذا &nbsp;الدواء بحسب تعليمات طبيبك بالضبط. إستشر طبيبك أو الصيدلي إذا لم تكن متأكداً. &nbsp;يتوفر دواء فامبيرا Fampyra بموجب وصفة طبية وتحت إشراف أطباء لديهم خبرة في مرض التصلب اللويحي المتعدد MS.</p><p dir="RTL">وسوف يعطي لك طبيبك وصفة مبدئية لمدة أسبوعين إلى أربعة اسابيع. &nbsp;وبعد أسبوعين إلى أربعة أسابيع سوف يعاد تقييم العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة</strong><strong> </strong><strong>الموصى</strong><strong> </strong><strong>بها</strong><strong> </strong><strong>هي</strong><strong>:</strong><strong> </strong></p><p dir="RTL"><strong>قرص</strong><strong> </strong><strong>واحد</strong><strong> </strong>في الصباح <strong>وقرص</strong><strong> </strong><strong>واحد</strong><strong> </strong>في المساء )بينهما فترة 12 ساعة.(لا تتناول أكثر من قرصين في اليوم.يجب عليك <strong>أن</strong><strong> </strong><strong>تنتظر</strong><strong> </strong><strong>لفترة</strong><strong> 12 </strong><strong>ساعة</strong><strong> </strong>قبل تناول القرص التالي.لا تتناول الأقراص قبل مرور فترة 12 ساعة من القرص السابق.</p><p dir="RTL">يُستخدم الدواء Fampyra عن طريق الفم.</p><p dir="RTL"><strong>ابتلع كل</strong><strong> </strong><strong>قرص</strong><strong> </strong><strong>بالكامل</strong><strong>،</strong> مع جرعة من الماء. <strong>&nbsp;</strong>لا تقسم أو تسحق أو تذيب أو تمص أو تمضغ القرص. فقد يؤدي ذلك إلى زيادة احتمال إصابتك بالأعراض الجانبية.</p><p dir="RTL">يجب تناول هذا الدواء بدون طعام وعلى معدة فارغة</p><p dir="RTL">ستحتوي القارورة أيضًا على مجفف. أترك مادة امتصاص الرطوبة والتجفيف في القارورة ولا تبتلعها.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>أقراص</strong><strong> </strong><strong>فامبيرا </strong><strong>&nbsp;&nbsp;Fampyra</strong><strong> بمعدل</strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>يجب</strong><strong> </strong><strong>عليك</strong></p><p dir="RTL"><strong>أتصل</strong><strong> </strong><strong>بطبيبك</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الحال</strong><strong> </strong>إذا تناولت عددًا أكبر من اللازم من الأقراص.</p><p dir="RTL">خذ علبة الدواء فامبيرا &nbsp;Fampyra &nbsp;معك إذا كنت ستذهب لمقابلة الطبيب.</p><p dir="RTL">في حالة تجاوز الجرعة، قد تلاحظ حدوث تعرق، إرتجاف طفيف (رعاش), دوخة, وتشوش وفقدان الذاكرة وتشنجات (النوبات المرضية) وقد تلاحظ أيضًا أعراض أخرى غير مذكورة هنا.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>قرص</strong><strong> </strong><strong>فامبيرا </strong><strong>Fampyra</strong></p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>قرص،</strong><strong> </strong>فلا تأخذ قرصين مرة واحدة لتعويض الجرعة المفقودة. ويجب عليك <strong>دائماً</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>تنتظر</strong><strong> </strong><strong>لمدة</strong><strong> 12 </strong><strong>ساعة</strong><strong> </strong>بين تناول كل قرص والآخر.</p><p dir="RTL">إذا كانت لديك أي اسئلة أخرى عن استعمال الدواء فامبيرا Fampyra فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">كسائر الأدوية، قد يسبب الدواء فامبيرا Fampyra &nbsp;أعراض جانبية رغم أنه ليس بالضرورة أن يعاني كل شخص من هذه الأعراض.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>أصبت</strong><strong> </strong><strong>بنوبة</strong><strong> </strong><strong>صرع</strong><strong> </strong><strong>فعليك التوقُّف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>الدواء</strong><strong> </strong><strong>فامبيرا</strong><strong> </strong><strong>Fampyra </strong>وإبلاغ &nbsp;طبيبك في الحال.</p><p dir="RTL">إذا واجهت واحدة أو أكثر من أعراض <strong>الحساسيّة المفرطة</strong><strong> </strong>التالية: تورّم الوجه، الفم، الشّفتين، الحلق أو اللسان، إحمرار أو حكّة في الجلد، ضيق في الصدر وصعوبة في التنفس <strong>توقف</strong><strong> </strong><strong>عن تناول فامبيرا </strong><strong>Fampyra</strong><strong> وراجع</strong><strong> </strong>طبيبك فورًا.</p><p dir="RTL">الأعراض الجانبية مذكورة فيما يلي بحسب معدلات تكرارها:</p><p dir="RTL"><strong>أعراض</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>شائعة</strong><strong> </strong><strong>جداً</strong></p><p dir="RTL">قد تؤثر على أكثر من شخص واحد من بين 10 أشخاص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المسالك البولية</p><p dir="RTL"><strong>أعراض</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>شائعة</strong></p><p dir="RTL">قد تؤثر على شخص واحد كحد أقصى من بين 10 أشخاص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم الثبات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار <em>(الترنُّح)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف والتعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرتجاف طفيف <em>(رعاش)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التنميل أو النخز في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزلات البرد <em>(التهاب البلعوم الأنفي</em><em>(</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زكام &nbsp;<em>(الأنفلونزا)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فيروسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس ) ضيق التنفس(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرغبة في القيء )الغثيان(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ الفعلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام الظهر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات القلب التي تشعر بها <em>(ضربات القلب السريعة) </em></p><p dir="RTL"><strong>أعراض جانبية غير شائعة</strong></p><p dir="RTL">قد تؤثر على شخص واحد كحد أقصى من بين 100 شخص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات التشنج المرضية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد الفعل التحسسي <em>(حساسية مفرطة)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساسية شديدة (رد فعل تأقي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه أو الشفتين أو الفم أو اللسان (وذمة وعائية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بدء ظهور أو تفاقم الألم العصبي في الوجه<em> )</em><em>الألم</em><em> </em><em>العصبي</em><em> </em><em>الثلاثي </em><em>التوائم</em><em>(</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معدل ضربات القلب السريع <em>(عدم انتظام دقات القلب)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة أو فقدان الوعي (انخفاض ضغط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي / الحكة (الشرى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم الراحة/ ألم في الصدر</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong><strong> </strong></p><p dir="RTL">إذا تعرضت لأيٍّ من الآثار الجانبية، استشِر طبيبك أو الصيدلي. ويشمل هذا أي آثار جانبية محتملة غير مُدرَجة في هذه النشرة. ويمكنك الإبلاغ عن الآثار الجانبية مباشرةً عن طريق نظام الإبلاغ الوطني المذكور في القسم 6 من هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك أن تساعد على تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">أبق هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المبين على العبوة بعد كلمة EXP( انتهاء الصلاحية.(ويُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير في ذلك الشهر.</p><p dir="RTL">يُحفظ في درجة حرارة أقل من &nbsp;25 درجة مئوية . يجب تخزين الأقراص في العبوة الأصلية حتى يمكن حمايتها من الضوء والرطوبة.</p><p dir="RTL">يجب فتح قارورة واحدة فقط في كل مرة. وبعد فتح القارورة لأول مرة، استعمل الدواء خلال مدة سبعة أيام.</p><p dir="RTL">يجب عدم التخلص من أية أدوية في مياه الصرف الصحي أو النفايات المنزلية. إسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تلزمك. ستساعدك هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong>يمكنك الحصول على نسخة من هذه النشرة مطبوعة بأحرف أكبر عن طريق الاتصال بالمندوب المحلي )أنظر القائمة أدناه(.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما</strong><strong> </strong><strong>هي</strong><strong> </strong><strong>محتويات</strong><strong> </strong><strong>الدواء</strong><strong> </strong><strong>فامبيرا</strong><strong>&nbsp; Fampyra </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المادة</strong><strong> </strong><strong>الفعالة</strong><strong> </strong>فامبريدين . fampridine</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل قرص طويل المفعول على 10 مللغرام من مادة فامبريدين . fampridine</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المكونات</strong><strong> </strong><strong>الأخرى</strong><strong> </strong>هي:</p><p dir="RTL">الجزء الداخلي من القرص: هايبروميلوز&nbsp; hypromellose، سيليولوز بلوري دقيق، سيليكا غروية لامائية، ستيارات الماغنيسيوم، الكسوة الغشائية: هايبروميلوز&nbsp;&nbsp; hypromellose، ثنائي أكسيد التيتانيوم ( E- 171) ، بولي اثيلين جلايكول .400</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف</strong><strong> </strong><strong>تبدو</strong><strong> </strong><strong>أقراص</strong><strong> </strong><strong>فامبيرا</strong><strong> Fampyra </strong><strong>وكيف</strong><strong> </strong><strong>تبدو</strong><strong> </strong><strong>محتويات</strong><strong> </strong><strong>العبوة</strong></p><p dir="RTL">فامبيرا Fampyra عبارة عن قرص ذي مفعول طويل الأمد بلون&nbsp; أبيض ضارب إلى الصفرة ومكسو بغشاء في شكلٍ بيضاوي محدب الوجهين&times; 13 8 مم مع وجود الأحرف A 10 على أحد الجانبين.&nbsp;</p><p dir="RTL">يأتي فامبيرا Fampyra في قارورات من البولي إيثيلين عالي الكثافة (HDPE). تحتوي كل قارورة على 14 قرصًا ممتد المفعول وعلى مادة مُجَفِّفه هي هلام السليكا. تحتوي كل عبوة على 56 قرصًا ممتد المفعول (4 قارورات).&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>حامل</u><u> </u><u>تفويض</u><u> </u><u>التسويق</u><u> </u><u>هو</u><u>:</u></p><p>Biogen Netherlands B.V.</p><p>Prins Mauritslaan 13</p><p>1171 LP Badhoevedorp</p><p>The Netherlands, هولندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المصنع</u><u>:</u></p><p dir="RTL">Alkermes Pharma Ireland Ltd, Monksland,</p><p dir="RTL">Athlone, Co. Westmeath, Ireland</p><p dir="RTL">إيرلندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             05/2022  
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                  Fampyra 10 mg prolonged-release tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Each prolonged-release tablet contains 10 mg of fampridine.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                  Prolonged-release tablet.

An off-white, film coated, oval biconvex 13 x 8 mm tablet with flat edge debossed with A10 on one side.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Fampyra is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">&nbsp;</p><p>Treatment with fampridine is restricted to prescription and supervision by physicians experienced in the management of MS.</p><p><strong>&nbsp;</strong></p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dose is one 10&nbsp;mg tablet, twice daily, taken 12&nbsp;hours apart (one tablet in the morning and one tablet in the evening). Fampridine should not be administered more frequently or at higher doses than recommended (see section 4.4). The tablets should be taken without food (see&nbsp;section 5.2).</p><p>&nbsp;</p><p><em>Missed dose</em></p><p><u>&nbsp;</u></p><p>The usual dosing regimen should always be followed. A double dose should not be taken if a dose is missed.</p><p>&nbsp;</p><p><u>Starting and evaluating Fampyra treatment</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Initial prescription should be limited to two to four weeks of therapy as clinical benefits should generally be identified within two to four weeks after starting Fampyra.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An assessment of walking ability, e.g. the Timed 25 Foot Walk (T25FW) or Twelve Item Multiple Sclerosis Walking Scale (MSWS-12), is recommended to evaluate improvement within two to four weeks. If no improvement is observed, the treatment should be discontinued.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicinal product should be discontinued if benefit is not reported by patients.</p><p><strong>&nbsp;</strong></p><p><u>Re-evaluating Fampyra treatment</u></p><p>&nbsp;</p><p>If decline in walking ability is observed, physicians should consider an interruption to treatment in order to reassess the benefits of fampridine (see above). The re-evaluation should include withdrawal of this medicinal product and performing an assessment of walking ability. Fampridine should be discontinued if patients no longer receive walking benefit.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Special populations</u></p><p><strong>&nbsp;</strong></p><p><em>Elderly </em></p><p>Renal function should be checked in the elderly before starting treatment with this medicinal product. Monitoring renal function to detect any renal impairment is recommended in the elderly (see section 4.4).</p><p>&nbsp;</p><p><em>Patients with renal impairment</em></p><p>Fampridine is contraindicated in patients with moderate and severe renal impairment (creatinine clearance &lt;50&nbsp;mL/min) (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><em>Patients with hepatic impairment</em></p><p>No dose adjustment is required for patients with hepatic impairment.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of this medicinal product in children aged 0 to 18&nbsp;years have not been established. No data are available.</p><p><em><u>&nbsp;</u></em></p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Fampyra is for oral use.</p><p>&nbsp;</p><p>The tablet must be swallowed whole. It must not be divided, crushed, dissolved, sucked or chewed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Hypersensitivity to fampridine or to any of the excipients listed in section 6.1.

Concurrent treatment with other medicinal products containing fampridine (4-aminopyridine).

Patients with prior history or current presentation of seizure. 

Patients with moderate or severe renal impairment (creatinine clearance <50 mL/min).

Concomitant use of Fampyra with medicinal products that are inhibitors of Organic Cation Transporter 2 (OCT2) for example, cimetidine.
 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Seizure risk</u></p><p>&nbsp;</p><p>Treatment with fampridine increases seizure risk (see section 4.8).</p><p>&nbsp;</p><p>This medicinal product should be administered with caution in the presence of any factors which may lower seizure threshold.</p><p>&nbsp;</p><p>Fampridine should be discontinued in patients who experience a seizure while on treatment.&nbsp;</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>Fampridine is primarily excreted unchanged by the kidneys. Patients with renal impairment have higher plasma concentrations which are associated with increased adverse reactions, in particular neurological effects. Determining renal function before treatment and its regular monitoring during treatment is recommended in all patients (particularly in the elderly in whom renal function might be reduced). Creatinine clearance can be estimated using the Cockroft-Gault formula.</p><p><u>&nbsp;</u></p><p>Caution is required when Fampyra is prescribed in patients with mild renal impairment or in patients using medicinal products that are substrates of OCT2 for example, carvedilol, propranolol and metformin.&nbsp;</p><p><u>&nbsp;</u></p><p><u>Hypersensitivity reactions</u></p><p><u>&nbsp;</u></p><p>In post-marketing experience, serious hypersensitivity reactions (including anaphylactic reaction) have been reported, the majority of these cases occurred within the first week of treatment. Particular attention should be given to patients with a previous history of allergic reactions. If an anaphylactic or other serious allergic reaction occurs, this medicinal product should be discontinued and not restarted.</p><p>&nbsp;</p><p><u>Other warnings and precautions</u></p><p>&nbsp;</p><p>Fampridine should be administered with caution to patients with cardiovascular symptoms of rhythm and sinoatrial or atrioventricular conduction cardiac disorders (these effects are seen in overdose). There is limited safety information in these patients.</p><p>&nbsp;</p><p>The increased incidence of dizziness and balance disorder seen with fampridine may result in an increased risk of falls. Therefore, patients should use walking aids as needed.</p><p>&nbsp;</p><p>In clinical studies low white blood cell counts were seen in 2.1% of Fampyra patients versus 1.9% of patients on placebo. Infections were seen in the clinical studies (see section 4.8) and increased infection rate and impairment of the immune response cannot be excluded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">&nbsp;</p><p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p><p>Concurrent treatment with other medicinal products containing fampridine (4-aminopyridine) is contraindicated (see section 4.3).</p><p>&nbsp;</p><p>Fampridine is eliminated mainly via the kidneys with active renal secretion accounting for about 60% (see section 5.2). OCT2 is the transporter responsible for the active secretion of fampridine. Thus, the concomitant use of fampridine with medicinal products that are inhibitors of OCT2 for example, cimetidine are contraindicated (see section 4.3) and concomitant use of fampridine with medicinal products that are substrates of OCT2 for example, carvedilol, propranolol and metformin is cautioned (see section 4.4).</p><p>&nbsp;</p><p><u>Interferon:</u> fampridine has been administered concomitantly with interferon-beta and no pharmacokinetic medicinal product interactions were observed.</p><p>&nbsp;</p><p style="text-align:justify"><u>Baclofen:</u> fampridine has been administered concomitantly with baclofen and no pharmacokinetic medicinal product interactions were observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are limited amount of data from the use of fampridine in pregnant women.</p><p>&nbsp;</p><p>Animal studies have shown reproductive toxicity (see section 5.3). As a precautionary measure it is preferable to avoid the use of fampridine in pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether fampridine is excreted in human or animal milk. Fampyra is not recommended during breast-feeding.</p><p>&nbsp;</p><p><u>Fertility </u></p><p><u>&nbsp;</u></p><p>In animal studies no effects on fertility were seen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">&nbsp;Fampyra has a moderate influence on the ability to drive and use machines (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">&nbsp;</p><p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The safety of Fampyra has been evaluated in randomised controlled clinical studies, in open label long term studies and in the post marketing setting.</p><p>&nbsp;</p><p>Adverse reactions identified are mostly neurological and include seizure, insomnia, anxiety, balance disorder, dizziness, paraesthesia, tremor, headache and asthenia. This is consistent with fampridine&rsquo;s pharmacological activity. The highest incidence of adverse reactions identified from placebo-controlled trials in multiple sclerosis patients with fampridine given at the recommended dose, are reported as urinary tract infection (in approximately 12% of patients).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions are presented below by system organ class and absolute frequency. Frequencies are defined as: very common (&ge;1/10); common (&ge;1/100 to &lt; 1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 1: Tabulated list of adverse reactions</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>MedDRA System Organ Class (SOC)</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Urinary tract infection<sup>1</sup></p><p>Influenza<sup>1</sup></p><p>Nasopharyngitis<sup>1</sup></p><p>Viral infection<sup>1</sup></p></td><td style="vertical-align:top"><p>Very Common</p><p>Common</p><p>Common</p><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Anaphylaxis</p><p>Angioedema</p><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>Uncommon</p><p>Uncommon</p><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Insomnia</p><p>Anxiety</p></td><td style="vertical-align:top"><p>Common</p><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness</p><p>Headache</p><p>Balance disorder</p><p>Vertigo</p><p>Paraesthesia</p><p>Tremor</p><p>Seizure<sup>2</sup></p><p>Trigeminal neuralgia<sup>3</sup></p></td><td style="vertical-align:top"><p>Common</p><p>Common</p><p>Common</p><p>Common</p><p>Common</p><p>Common</p><p>Uncommon</p><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hypotension<sup>4</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Dyspnoea</p><p>Pharyngolaryngeal pain</p></td><td style="vertical-align:top"><p>Common</p><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea</p><p>Vomiting</p><p>Constipation</p><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Common</p><p>Common</p><p>Common</p><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash</p><p>Urticaria</p></td><td style="vertical-align:top"><p>Uncommon</p><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Asthenia</p><p>Chest discomfort<sup>4</sup></p></td><td style="vertical-align:top"><p>Common</p><p>Uncommon</p></td></tr></tbody></table><p><sup>1</sup> See section 4.4</p><p><sup>2 </sup>See sections 4.3 and 4.4</p><p><sup>3</sup> Includes both <em>de novo</em> symptoms and exacerbation of existing trigeminal neuralgia</p><p><sup>4 </sup>These symptoms were observed in the context of hypersensitivity</p><p><u>&nbsp;</u></p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Hypersensitivity</em></p><p><em><u>&nbsp;</u></em></p><p>In post-marketing experience, there have been reports of hypersensitivity reactions (including anaphylaxis) which have occurred with one or more of the following: dyspnoea, chest discomfort, hypotension, angioedema, rash and urticaria. For further information on hypersensitivity reactions, please refer to sections 4.3 and 4.4.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>&nbsp;</p><p><strong>To report any side effects:</strong></p><p>&nbsp;</p><ul><li><strong>Saudi Arabia:</strong></li></ul><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Center (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>&nbsp;</p><p>Acute symptoms of overdose with fampridine were consistent with central nervous system excitation and included confusion, tremulousness, diaphoresis, seizure, and amnesia.&nbsp;</p><p>&nbsp;</p><p>Central nervous system adverse reactions at high doses of 4-aminopyridine include dizziness, confusion, seizures, status epilepticus, involuntary and choreoathetoid movements. Other side effects at high doses include cases of cardiac arrhythmias (for example, supraventricular tachycardia and bradycardia) and ventricular tachycardia as a consequence of potential QT prolongation. Reports of hypertension have also been received.</p><p><u>&nbsp;</u></p><p><u>Management</u></p><p><u>&nbsp;</u></p><p>Patients who overdose should be provided supportive care. Repeated seizure activity should be treated with benzodiazepine, phenytoin, or other appropriate acute anti-seizure therapy.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Pharmacotherapeutic group: Other nervous system drugs, ATC code: N07XX07.</p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Fampyra is a potassium channel blocker. By blocking potassium channels, fampridine reduces the leakage of ionic current through these channels, thereby prolonging repolarization and thus enhancing action potential formation in demyelinated axons and neurological function. Presumably, by enhancing action potential formation, more impulses might be conducted in the central nervous system.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><u>&nbsp;</u></p><p>Three phase III, randomised, double-blind, placebo controlled confirmatory studies, (MS-F203 and MS-F204 and 218MS305) have been performed. The proportion of responders was independent of concomitant immunomodulatory therapy (including interferons, glatiramer acetate, fingolimod and natalizumab). The Fampyra dose was 10&nbsp;mg twice a day (BID).</p><p>&nbsp;</p><p><em>Studies MS-F203 and MS-F204</em></p><p>&nbsp;</p><p>The primary endpoint in studies MS-F203 and MS-F204 was the responder rate in walking speed as measured by the Timed 25‑foot Walk (T25FW). A responder was defined as a patient who consistently had a faster walking speed for at least three visits out of a possible four during the double blind period as compared to the maximum value among five off-treatment visits.</p><p>&nbsp;</p><p>A significantly greater proportion of Fampyra treated patients were responders as compared to placebo (MS‑F203: 34.8%&nbsp;vs.&nbsp;8.3%, p&lt;0.001; MS‑F204: 42.9%&nbsp;vs.&nbsp;9.3%, p&lt;0.001). <s>&nbsp;</s></p><p>&nbsp;</p><p>Patients who responded to Fampyra increased their walking speed on average by 26.3% vs 5.3% on placebo (p&lt;0.001) (MS-F203) and 25.3% vs 7.8% (p&lt; 0.001) (MS-F204). The improvement appeared rapidly (within weeks) after starting the treatment.&nbsp;</p><p>&nbsp;</p><p>Statistically and clinically meaningful improvements in walking were seen, as measured by the 12- item Multiple Sclerosis Walking Scale.<strong>Table 2: Studies MS-F203 and MS-F204</strong></p><p><em><u>&nbsp;</u></em></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>STUDY *</p></td><td colspan="2" style="vertical-align:top"><p><strong>MS-F203</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>MS-F204</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><sup>&nbsp;</sup></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Fampyra</strong></p><p><strong>10 mg BID</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Fampyra</strong></p><p><strong>10 mg BID</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>n of subjects</p></td><td style="vertical-align:top"><p>72</p></td><td style="vertical-align:top"><p>224</p></td><td style="vertical-align:top"><p>118</p></td><td style="vertical-align:top"><p>119</p></td></tr></tbody><thead><tr><td style="vertical-align:top"><p><sup>&nbsp;</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Consistent improvement</strong></p></td><td style="vertical-align:top"><p><strong>8.3%</strong></p></td><td style="vertical-align:top"><p><strong>34.8%</strong></p></td><td style="vertical-align:top"><p><strong>9.3%</strong></p></td><td style="vertical-align:top"><p><strong>42.9%</strong></p></td></tr><tr><td style="vertical-align:top"><p>Difference</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>26.5%</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>33.5%</strong></p></td></tr><tr><td style="vertical-align:top"><p>CI<sub>95%</sub></p><p>P-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>17.6%, 35.4%</p><p>&lt; 0.001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>23.2%, 43.9%</p><p>&lt; 0.001</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge;20% improvement</strong></p></td><td style="vertical-align:top"><p>11.1%</p></td><td style="vertical-align:top"><p>31.7%</p></td><td style="vertical-align:top"><p>15.3%</p></td><td style="vertical-align:top"><p>34.5%</p></td></tr><tr><td style="vertical-align:top"><p>Difference</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>20.6%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>19.2%</p></td></tr><tr><td style="vertical-align:top"><p>CI<sub>95%</sub></p><p>P-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>11.1%,30.1%</p><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>8.5%,29.9%</p><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Walking speed Feet/sec</p></td><td style="vertical-align:top"><p>Ft per sec</p></td><td style="vertical-align:top"><p>Ft per sec</p></td><td style="vertical-align:top"><p>Ft per sec</p></td><td style="vertical-align:top"><p>Ft per sec</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>2.04</p></td><td style="vertical-align:top"><p>2.02</p></td><td style="vertical-align:top"><p>2.21</p></td><td style="vertical-align:top"><p>2.12</p></td></tr><tr><td style="vertical-align:top"><p>Endpoint</p></td><td style="vertical-align:top"><p>2.15</p></td><td style="vertical-align:top"><p>2.32</p></td><td style="vertical-align:top"><p>2.39</p></td><td style="vertical-align:top"><p>2.43</p></td></tr><tr><td style="vertical-align:top"><p>Change</p></td><td style="vertical-align:top"><p>0.11</p></td><td style="vertical-align:top"><p>0.30</p></td><td style="vertical-align:top"><p>0.18</p></td><td style="vertical-align:top"><p>0.31</p></td></tr><tr><td style="vertical-align:top"><p>Difference</p></td><td colspan="2" style="vertical-align:top"><p>0.19</p></td><td colspan="2" style="vertical-align:top"><p>0.12</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.010</p></td><td colspan="2" style="vertical-align:top"><p>0.038</p></td></tr><tr><td style="vertical-align:top"><p>Average % Change</p></td><td style="vertical-align:top"><p>5.24</p></td><td style="vertical-align:top"><p>13.88</p></td><td style="vertical-align:top"><p>7.74</p></td><td style="vertical-align:top"><p>14.36</p></td></tr><tr><td style="vertical-align:top"><p>Difference</p></td><td colspan="2" style="vertical-align:top"><p>8.65</p></td><td colspan="2" style="vertical-align:top"><p>6.62</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>&lt; 0.001</p></td><td colspan="2" style="vertical-align:top"><p>0.007</p></td></tr><tr><td style="vertical-align:top"><p>MSWS-12-score (mean, sem)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>69.27 (2.22)</p></td><td style="vertical-align:top"><p>71.06 (1.34)</p></td><td style="vertical-align:top"><p>67.03 (1.90)</p></td><td style="vertical-align:top"><p>73.81 (1.87)</p></td></tr><tr><td style="vertical-align:top"><p>Average change</p></td><td style="vertical-align:top"><p>-0.01 (1.46)</p></td><td style="vertical-align:top"><p>-2.84 (0.878)</p></td><td style="vertical-align:top"><p>0.87 (1.22)</p></td><td style="vertical-align:top"><p>-2.77 (1.20)</p></td></tr><tr><td style="vertical-align:top"><p>Difference</p></td><td colspan="2" style="vertical-align:top"><p>2.83</p></td><td colspan="2" style="vertical-align:top"><p>3.65</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.084</p></td><td colspan="2" style="vertical-align:top"><p>0.021</p></td></tr><tr><td style="vertical-align:top"><p>LEMMT (mean, sem)</p><p>(Lower Extremity Manual Muscle Test)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>3.92 (0.070)</p></td><td style="vertical-align:top"><p>4.01 (0.042)</p></td><td style="vertical-align:top"><p>4.01 (0.054)</p></td><td style="vertical-align:top"><p>3.95 (0.053)</p></td></tr><tr><td style="vertical-align:top"><p>Average change</p></td><td style="vertical-align:top"><p>0.05 (0.024)</p></td><td style="vertical-align:top"><p>0.13 (0.014)</p></td><td style="vertical-align:top"><p>0.05 (0.024)</p></td><td style="vertical-align:top"><p>0.10 (0.024)</p></td></tr><tr><td style="vertical-align:top"><p>Difference</p></td><td colspan="2" style="vertical-align:top"><p>0.08</p></td><td colspan="2" style="vertical-align:top"><p>0.05</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.003</p></td><td colspan="2" style="vertical-align:top"><p>0.106</p></td></tr><tr><td style="vertical-align:top"><p>Ashworth Score</p><p>(A test for muscle</p><p>spasticity)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>0.98 (0.078)</p></td><td style="vertical-align:top"><p>0.95 (0.047)</p></td><td style="vertical-align:top"><p>0.79 (0.058)</p></td><td style="vertical-align:top"><p>0.87 (0.057)</p></td></tr><tr><td style="vertical-align:top"><p>Average change</p></td><td style="vertical-align:top"><p>-0.09 (0.037)</p></td><td style="vertical-align:top"><p>-0.18 (0.022)</p></td><td style="vertical-align:top"><p>-0.07 (0.033)</p></td><td style="vertical-align:top"><p>-0.17 (0.032)</p></td></tr><tr><td style="vertical-align:top"><p>Difference</p></td><td colspan="2" style="vertical-align:top"><p>0.10</p></td><td colspan="2" style="vertical-align:top"><p>0.10</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.021</p></td><td colspan="2" style="vertical-align:top"><p>0.015</p></td></tr></tbody></table><p>BID = twice a day</p><p>&nbsp;</p><p><em>Study 218MS305</em></p><p><em>&nbsp;</em></p><p>Study 218MS305 was conducted in 636 subjects with multiple sclerosis and walking disability. Duration of double-blind treatment was 24 weeks with a 2 week post&ndash;treatment follow-up. The primary endpoint was improvement in walking ability, measured as the proportion of patients achieving a mean improvement of &ge; 8 points from baseline MSWS-12 score over 24 weeks. In this study there was a statistically significant treatment difference, with a greater proportion of Fampyra treated patients demonstrating an improvement in walking ability, compared to placebo-controlled patients (relative risk of 1.38 (95% CI: [1.06, 1.70]).&nbsp; Improvements generally appeared within 2 to 4 weeks of initiation of treatment, and disappeared within 2 weeks of treatment cessation.</p><p>&nbsp;</p><p>Fampridine treated patients also demonstrated a statistically significant improvement in the Timed Up and Go (TUG) test, a measure of static and dynamic balance and physical mobility. In this secondary endpoint, a greater proportion of fampridine treated patients achieved &ge; 15% mean improvement from baseline TUG speed over a 24 week period, compared to placebo. The difference in the Berg Balance Scale (BBS; a measure of static balance), was not statistically significant.</p><p>&nbsp;</p><p>In addition, patients treated with Fampyra demonstrated a statistically significant mean improvement from baseline compared to placebo in the Multiple Sclerosis Impact Scale (MSIS-29) physical score (LSM difference -3.31, p&lt;0.001).</p><p><strong>&nbsp;</strong></p><p><strong>Table 3: Study 218MS305</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Over 24 weeks</strong></p></td><td style="vertical-align:top"><p><strong>Placebo<br />N = 318*</strong></p></td><td style="vertical-align:top"><p><strong>Fampyra 10 mg BID<br />N = 315*</strong></p></td><td style="vertical-align:top"><p><strong>Difference (95% CI)</strong></p><p><strong><em>p</em></strong><strong> - value</strong></p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients with mean improvement of &ge;&nbsp;8 points from baseline MSWS‑12 score</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>34%</p></td><td style="vertical-align:top"><p>43%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Risk difference: 10.4%</p><p>(3% ; 17.8%)</p><p>0.006</p></td></tr><tr><td style="vertical-align:top"><p><strong>MSWS-12 score </strong></p><p>Baseline&nbsp;&nbsp;</p><p>Improvement from baseline</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>65.4</p><p>-2.59</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>63.6</p><p>-6.73</p></td><td style="vertical-align:top"><p>LSM: -4.14</p><p>(-6.22 ; -2.06)</p><p>&lt;0.001</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>TUG</strong></p><p>Proportion of patients with mean improvement of &ge;&nbsp;15% in TUG speed</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>35%</p></td><td style="vertical-align:top"><p>43%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Risk difference: 9.2% (0.9% ; 17.5%)</p><p>0.03</p></td></tr><tr><td style="vertical-align:top"><p><strong>TUG </strong></p><p>Baseline</p><p>Improvement from baseline (sec)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>27.1</p><p>-1.94</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>24.9</p><p>-3.3</p></td><td style="vertical-align:top"><p>LSM: -1.36</p><p>(-2.85 ; 0.12)</p><p>0.07</p></td></tr><tr><td style="vertical-align:top"><p><strong>MSIS-29 physical score </strong></p><p>Baseline</p><p>Improvement from baseline</p></td><td style="vertical-align:top"><p>55.3</p><p>-4.68</p></td><td style="vertical-align:top"><p>52.4</p><p>-8.00</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>LSM: -3.31</p><p>(-5.13 ; -1.50)</p><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>BBS score</strong></p><p>Baseline</p><p>Improvement from baseline</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>40.2</p><p>1.34</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>40.6</p><p>1.75</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>LSM: 0.41</p><p>(-0.13 ; 0.95)</p><p>0.141</p></td></tr></tbody></table><p>*Intent to treat population = 633; LSM = Least square mean, BID = twice a day</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>Orally administered fampridine is rapidly and completely absorbed from the gastrointestinal tract. Fampridine has a narrow therapeutic index. Absolute bioavailability of Fampyra prolonged-release tablets has not been assessed, but relative bioavailability (as compared to an aqueous oral solution) is 95%. The Fampyra prolonged-release tablet has a delay in the absorption of fampridine manifested by slower rise to a lower peak concentration, without any effect on the extent of absorption.&nbsp;</p><p>&nbsp;</p><p>When Fampyra prolonged-release tablets are taken with food, the reduction in the area under the plasma concentration-time curve (AUC<sub>0-&infin;</sub>) of fampridine is approximately 2‑7% (10&nbsp;mg dose). The small reduction in AUC is not expected to cause a reduction in the therapeutic efficacy. However, C<sub>max</sub> increases by 15-23%. Since there is a clear relationship between C<sub>max</sub> and dose related adverse reactions, it is recommended to take Fampyra without food (see section 4.2).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Fampridine is a lipid-soluble active substance which readily crosses the blood-brain barrier. Fampridine is largely unbound to plasma proteins (bound fraction varied between 3-7% in human plasma). Fampridine has a volume of distribution of approximately 2.6&nbsp;L/kg.</p><p>Fampridine is not a substrate for P-glycoprotein.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>Fampridine is metabolised in humans by oxidation to 3‑hydroxy‑4‑aminopyridine and further conjugated to the 3‑hydroxy‑4‑aminopyridine sulfate. No pharmacological activity was found for the fampridine metabolites against selected potassium channels <em>in vitro</em>.</p><p>&nbsp;</p><p>The 3‑hydroxylation of fampridine to 3‑hydroxy‑4‑aminopyridine by human liver microsomes appeared to be catalysed by Cytochrome P450 2E1 (CYP2E1).</p><p>&nbsp;</p><p>There was evidence of direct inhibition of CYP2E1 by fampridine at 30&nbsp;&mu;M (approximately 12% inhibition) which is approximately 100 times the average plasma fampridine concentration measured for the 10&nbsp;mg tablet.</p><p>&nbsp;</p><p>Treatment of cultured human hepatocytes with fampridine had little or no effect on induction of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2E1 or CYP3A4/5 enzyme activities.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>The major route of elimination for fampridine is renal excretion, with approximately 90% of the dose recovered in urine as parent active substance within 24 hours. Renal clearance (CLR 370&nbsp;mL/min) is substantially greater than glomerular filtration rate due to combined glomerular filtration and active excretion by the renal OCT2 transporter. Faecal excretion accounts for less than 1% of the administered dose.</p><p>&nbsp;</p><p>Fampridine is characterized by linear (dose-proportional) pharmacokinetics with a terminal elimination half-life of approximately 6&nbsp;hours. The maximum plasma concentration (C<sub>max</sub>) and, to a smaller extent, area under the plasma concentration-time curve (AUC) increase proportionately with dose. There is no evidence of clinically relevant accumulation of fampridine taken at the recommended dose in patients with full renal function. In patients with renal impairment, accumulation occurs relative to the degree of impairment.&nbsp;</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p><u>&nbsp;</u></p><p>&nbsp;Fampridine is primarily excreted unchanged by the kidneys, and with creatinine clearance known to decrease with age, monitoring of renal function in elderly patients is recommended (see section 4.2).&nbsp;</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p><u>&nbsp;</u></p><p>No data are available.</p><p>&nbsp;</p><p><em>Patients with renal impairment</em></p><p><u>&nbsp;</u></p><p>Fampridine is eliminated primarily by the kidneys as unchanged active substance and therefore renal function should be checked in patients where renal function might be compromised. Patients with mild renal impairment can be expected to have approximately 1.7 to 1.9 times the fampridine concentrations achieved by patients with normal renal function. Fampyra must not be administered to patients with moderate and severe renal impairment (see sections 4.3 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Fampridine was studied in oral repeat dose toxicity studies in several animal species.</p><p>&nbsp;</p><p>Adverse responses to orally administered fampridine were rapid in onset, most often occurring within the first 2&nbsp;hours post-dose. Clinical signs evident after large single doses or repeated lower doses were similar in all species studied and included tremors, convulsions, ataxia, dyspnoea, dilated pupils, prostration, abnormal vocalization, increased respiration, and excess salivation. Gait abnormalities and hyper-excitability were also observed. These clinical signs were not unexpected and represent exaggerated pharmacology of fampridine. In addition, single cases of fatal urinary tract obstructions were observed in rats. The clinical relevance of these findings remains to be elucidated, but a causal relationship with fampridine treatment cannot be excluded.</p><p>&nbsp;</p><p>In reproduction toxicity studies in rats and rabbits, decreased weight and viability of foetuses and offspring were observed at maternally toxic doses. However, no increased risk for malformations or adverse effects on fertility was noted.</p><p>&nbsp;</p><p>In a battery of <em>in vitro </em>and <em>in vivo </em>studies fampridine did not show any potential to be mutagenic, clastogenic or carcinogenic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p><u>&nbsp;</u></p><p>Hypromellose</p><p>Microcrystalline cellulose</p><p>Silica, colloidal anhydrous</p><p>Magnesium stearate</p><p><em><u>&nbsp;</u></em></p><p><u>Film-coat</u></p><p><u>&nbsp;</u></p><p>Hypromellose</p><p>Titanium dioxide (E-171)</p><p>Polyethylene glycol 400</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                  18 months 

After first opening a bottle, use within 7 days.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Store below 30&deg;C. Store the tablets in the original packaging in order to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><strong>Bottles</strong></p><p>HDPE (high-density polyethylene) bottle with polypropylene caps, each bottle contains 14&nbsp;tablets and a silica gel desiccant.</p><p>Pack size of 56 (4 bottles of 14) tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Biogen Netherlands B.V.
Prins Mauritslaan 13
1171 LP Badhoevedorp
The Netherlands

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 May 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>